Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (11-20 of 426) with videos related to

Pageof 43
Sort By:
European Journal of Heart Failure|December 19, 2017
Keeping the right track in the treatment of patients with type 2 diabetesAngelo Avogaro
Giornale Italiano Di Cardiologia (2006)|April 20, 2016
[Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 14, 2011
[Cardioprotective effects of glucagon-like peptide-1: preclinical and clinical data]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 22, 2012
[Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 24, 2013
[Effects of anti-diabetic therapy on cardiovascular disease]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|February 3, 2017
[Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention]Angelo Avogaro
European Journal of Internal Medicine|August 18, 2024
It is time to get all the job done: For patients' sakeAngelo Avogaro
Giornale Italiano Di Cardiologia (2006)|April 1, 2016
[Cardiovascular disease prevention in adults with type 2 diabetes mellitus according to the recent statement from the American Heart Association/American Diabetes Association]Angelo Avogaro
Diabetes Care|September 28, 2011
Postprandial glucose: marker or risk factor?Angelo Avogaro
Reviews in Endocrine & Metabolic Disorders|March 23, 2021
Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectivesFederico Boscari, Angelo Avogaro
Pageof 43

Showing results (11-20 of 426) with videos related to

Sort By:
Pageof 43
European Journal of Heart Failure|December 19, 2017
Keeping the right track in the treatment of patients with type 2 diabetesAngelo Avogaro
Giornale Italiano Di Cardiologia (2006)|April 20, 2016
[Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 14, 2011
[Cardioprotective effects of glucagon-like peptide-1: preclinical and clinical data]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 22, 2012
[Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 24, 2013
[Effects of anti-diabetic therapy on cardiovascular disease]Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|February 3, 2017
[Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention]Angelo Avogaro
European Journal of Internal Medicine|August 18, 2024
It is time to get all the job done: For patients' sakeAngelo Avogaro
Giornale Italiano Di Cardiologia (2006)|April 1, 2016
[Cardiovascular disease prevention in adults with type 2 diabetes mellitus according to the recent statement from the American Heart Association/American Diabetes Association]Angelo Avogaro
Diabetes Care|September 28, 2011
Postprandial glucose: marker or risk factor?Angelo Avogaro
Reviews in Endocrine & Metabolic Disorders|March 23, 2021
Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectivesFederico Boscari, Angelo Avogaro
Pageof 43